Invitation to the presentation of ALKs first quarter 2025 results on Tuesday, 6 May 2025
ALK (ALKB.DC / OMX: ALK B) will publish its results for the…
Annual General Meeting in ALK-Abell A/S held on 13 March 2025
ALK (ALKB:DC / OMX: ALK B / AKBLF): ALK-Abelló A/S held its…
Report on transactions with ALK-Abell A/S B shares and associated securities by managerial staff
Accessibility: Skip TopNav ALK (ALKB:DC / OMX: ALK B / AKBLF): In…
ALKs house dust mite tablet (ACARIZAX) now recommended by NICE for use in the UK health system
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the…
ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered…